Rooted in Science, Inspired by Patients

Investor Presentation

May 2024
This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Towards 2030:
Evolving Into a Fully Integrated Biotech Innovation Powerhouse

Core Purpose
Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics.

Our Strategy
✓ Focus on core competence
✓ Turn science into medicine
✓ Build a profitable & successful biotech

Vision
By 2030, our KYSO® antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
Solid Track Record and Financial Foundation Fuel Our Growth

- Over 40 cumulative INDs since 1999
- Innovative clinical pipeline: 10 Genmab owned ≥50%
- 8 approved medicines based on Genmab’s innovation and antibody expertise
- Two approved medicines: Tivdak® (tisotumab vedotin-tftv) and EPKINLY®/TEPKINLY® (epcoritamab)
- Growing recurring revenue
- Sustainably profitable with cash position of ~USD 4.2B
- Investing in our capabilities
- Experienced, international leadership team

Tivdak is being co-developed and co-promoted by Genmab and Pfizer. EPKINLY is being co-developed and co-promoted by Genmab and AbbVie
The Genmab Model

Deep insight into antibody biology & disease targets

Proprietary technologies enable us to build a world-class pipeline

Match in-house expertise with strategic collaborations & partnerships

Strong pipeline of potential 1st-in-class / best-in-class products
Innovative Clinical Pipeline: Genmab Proprietary* and Partnered Products - Most Advanced Development Phase

### Early Clinical Development

- GEN1053 (HexaBody\textsuperscript{©}-CD27, BNT313)\textsuperscript{1}
- GEN1059 (DuoBody\textsuperscript{©}-EpCAMx4-1BB, BNT314)\textsuperscript{1}
- GEN1056 (BNT322)\textsuperscript{1}
- GEN3017 (DuoBody-CD3xCD30)

### Phase 2

- Acasunlimab (GEN1046/BNT311, DuoBody-PD-L1x4-1BB)\textsuperscript{1}
- GEN1042 (DuoBody-CD40x4-1BB, BNT312)\textsuperscript{1}
- GEN3014 (HexaBody-CD38)\textsuperscript{2}
- GEN1047 (DuoBody-CD3xB7H4)

### Phase 3

- Tisotumab vedotin (Tivdak)\textsuperscript{4}
- Ordesekimab\textsuperscript{5}
- Lu AF82422\textsuperscript{6}
- Inclacumab\textsuperscript{8}
- Mim8\textsuperscript{9}
- Daratumumab (DARZALEX\textsuperscript{®})\textsuperscript{7}
- Amivantamab (RYBREVANT\textsuperscript{®})\textsuperscript{7}
- Teclistamab (TECVAYLI\textsuperscript{®})\textsuperscript{7}
- Talquetamab (TALVEY\textsuperscript{™})\textsuperscript{7}
- Ofatumumab (Kesimpta\textsuperscript{®})\textsuperscript{10}
- Teprotumumab (TEPEZZA\textsuperscript{®})\textsuperscript{11}

### Approved‡

- Epcoritamab (EPKINLY)\textsuperscript{3}

---

\*Products where Genmab has ownership of at least 50%
\*Co-development with BioNTech; \*Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen; \*Co-development with AbbVie; \*Co-development with Seagen (Pfizer) \*Development by Sanofi;
\*Development by Lundbeck; \*Development and/or discovery by Janssen; \*Development by Pfizer (Global Blood Therapeutics);
\*Development by Novo Nordisk; \*Development by Novartis; \*Development by Amgen

© Genmab 2024
Power of Discovery and Drug Development Engine

- Over 20 in Current Clinical Development or Approved
  - 8 Approved
  - 2 Phase 3
  - 6 Phase 2
  - 1 Phase 1/2
  - 4 Phase 1

- >40 Cumulative INDs

- 8 Product Approvals

2024 Revenue Guidance: $2.8bn - $3.0bn

End-Market: $17.5bn*

- Genmab Proprietary Pipeline
  - From 2 in development in 2017 to 2 approved and 10 in development by 2024

Genmab cumulative investments 2017 to 2023 is ~$5bn** of which ~75% in R&D

*Company Collected Consensus pre 4Q 2023
**Sum of operating expenses 2017 to 2023 converted at USD/DKK 6.8

For Investor audience only. Not for public information or use. Not for promotional use.
World-class R&D Engine

Innovative Technologies Powering Our Pipeline

- DuoBody, 47%
- HexaBody, 24%
- Mix/Other, 29%

- DuoBody technology
- HexaBody technology
- DuoHexaBody® technology
- HexElect® technology
EPKINLY/TEPKINLY (epcoritamab) Approved in the U.S., Europe and Japan

Approved in U.S., Europe, Japan and other territories\(^1\)

- First bispecific antibody in U.S. to treat adults with R/R DLBCL\(^1\)
- First and only SC bispecific antibody in Europe to treat adults with R/R DLBCL\(^1\)
- First and only bispecific antibody in Japan to treat adults with certain types of R/R LBCL\(^1\)

Bispecific antibody delivered as off the shelf, rapid, SC injection, studied in B-NHL\(^2,3\)

Mechanism of Action


TCR, T-cell receptor.
## Broad & Comprehensive Epcoritamab Development Plan

<table>
<thead>
<tr>
<th>B-NHL Type</th>
<th>Intervention</th>
<th>Most Advanced Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Front-line</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DLBCL</strong></td>
<td>Epcoritamab + R-CHOP</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Anthracycline ineligible elderly patients</td>
<td>Epcoritamab +/- lenalidomide</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab + pola-R-CHP</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td><strong>FL</strong></td>
<td>Epcoritamab + R²</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab + BR</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td><strong>Relapsed or refractory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DLBCL</strong></td>
<td>Epcoritamab + lenalidomide</td>
<td>Phase 3</td>
</tr>
<tr>
<td>ASCT ineligible patients</td>
<td>Epcoritamab vs SOC</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab + lenalidomide</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab + lenalidomide + ibrutinib</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td>ASCT eligible patients</td>
<td>Epcoritamab + R-DHAX/C</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td>ASCT eligible patients</td>
<td>Epcoritamab + R-ICE</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td>ASCT eligible patients</td>
<td>Epcoritamab + Salvage</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab + GemOx</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td><strong>FL</strong></td>
<td>Epcoritamab + R²</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td><strong>DLBCL &amp; FL</strong></td>
<td>Epcoritamab monotherapy</td>
<td>Phase 2</td>
</tr>
<tr>
<td><strong>B-NHL</strong></td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1</td>
</tr>
<tr>
<td>DLBCL, FL, MCL</td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td>Japanese patients</td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Pediatric patients</td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Chinese patients</td>
<td>Epcoritamab monotherapy and + SOC</td>
<td>Phase 1</td>
</tr>
<tr>
<td><strong>CLL</strong></td>
<td>Epcoritamab + venetoclax</td>
<td>Phase 2*</td>
</tr>
<tr>
<td>Double-exposed CLL</td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1b/2</td>
</tr>
<tr>
<td>CLL</td>
<td>Epcoritamab monotherapy</td>
<td>Phase 1b/2</td>
</tr>
</tbody>
</table>

*B-NHL: B-cell Non-Hodgkin Lymphoma; BR: bendamustine + rituximab; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; SOC: standard of care; R² = Revlimid + rituximab; pola-R-CHP: polatuzumab vedotin, rituximab, cyclophosphamide, HCL, prednisone; R-ICE = rituximab, ifosfamide, carboplatin, and etoposide phosphate

For Investor audience only. Not for public information or use. Not for promotional use.

*Trial sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)
Tivdak (tisotumab vedotin-tftv)
Approved in the U.S.

- U.S. FDA: recurrent or metastatic cervical cancer with disease progression on or after chemo*
- First and only approved ADC for this population
- First Genmab-owned therapy to receive regulatory approval
- Pursuing potential in early lines of cervical cancer and in other solid tumors

*See U.S. prescribing information for full indication and safety information.
**Acasunlimab**
(GEN1046/BNT311, DuoBody-PD-L1x4-1BB)
- Potential first-in-class, bispecific next gen. immunotherapy
- Potential in solid tumors
- Encouraging clinical activity & manageable safety¹
- Phase 2 trial in NSCLC²

---

**GEN1042**
(BNT312, DuoBody-CD40x4-1BB)
- Potential first-in-class bispecific next gen. immunotherapy
- Potential in solid tumors
- Encouraging clinical activity & manageable safety³
- Phase 1/2 trials incl. expansion cohorts, combination therapy with pembrolizumab and chemo, currently enrolling

---

**GEN1053**
(BNT313, HexaBody-CD27)
- Proprietary HexaBody technology
- Potential in solid tumors
- In pre-clinical studies *in vitro* and *in vivo*, GEN1053 increased T-cell activation, proliferation, cytokine secretion, cytotoxic activity⁴
- FiH study in solid tumors currently ongoing

---

**GEN1059**
(BNT314, DuoBody-EpCAMx4-1BB)
- Potential in solid tumors
- Aimed at boosting antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity
- Phase 1/2 clinical trial of GEN1059 in solid tumors is ongoing

---

2. See clinicaltrials.gov for specific trial details

© Genmab 2024

For Investor audience only. Not for public information or use. Not for promotional use.

50:50 Collaboration with BioNTech for all investigational medicines
Genmab Owned Investigational Medicines in Clinical Development

**GEN3014**
(HexaBody-CD38)

- Proprietary HexaBody technology
- Potentially add to/broaden DARZALEX franchise
- Developing under exclusive WW license and option agreement with Janssen
- Phase 1/2 trial in R/R hem. malig. ongoing incl. cohort in R/R multiple myeloma, head-to-head with daratumumab

**GEN1047**
(DuoBody-CD3xB7H4)

- Proprietary DuoBody technology
- In pre-clin. studies induced T-cell mediated cytotoxicity of B7H4-positive tumor cells
- Potential in solid cancer indications known to express B7H4
- Phase 1/2 trial in solid tumors ongoing

**GEN3017**
(DuoBody-CD3xCD30)

- Proprietary DuoBody technology
- Potential in hematologic malignancies
- In pre-clin. studies induced potent T-cell mediated cytotoxicity of CD30-expressing tumor cells
- Phase 1/2 trial in R/R classical Hodgkin lymphoma and NHL

For Investor audience only. Not for public information or use. Not for promotional use.
Building Our Capabilities

**Research**
- Track record of success and investing for tomorrow
  - State-of-the-art facilities
  - Novel technologies and formats
  - External innovation

**Development**
- Scaling up to expand from early to late stage
  - Clinical development & operations
  - Disease area expertise
  - Medical Affairs, Translational Research, Safety and Regulatory

**Commercialization**
- Evolving into end-to-end, fully integrated biotech
  - Experienced team in place
  - Focused on U.S. and Japan
  - Two approved medicines: Tivdak & EPKINLY

Enabling functions to support growth & manage risk

Data Sciences to drive insights

For Investor audience only. Not for public information or use. Not for promotional use.
## Approved Antibody Therapeutics Incorporating Genmab’s Innovation

<table>
<thead>
<tr>
<th>Antibody Therapeutic</th>
<th>Developed And Commercialized By</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DARZALEX</strong> (daratumumab)</td>
<td>Janssen</td>
<td>Redefining Treatment of Multiple Myeloma (MM)*</td>
</tr>
<tr>
<td><strong>RYBRENT</strong> (amivantamab-vmjw)</td>
<td>Co-discovered, developed &amp; commercialized by Janssen</td>
<td>Approved in U.S. &amp; EU for patients with locally advanced or metastatic NSCLC with EGFR Exon 20 insertion mutations*</td>
</tr>
<tr>
<td><strong>Kesimpta</strong> (ofatumumab)</td>
<td>Commercialized by Novartis</td>
<td>Approved in U.S., EU &amp; Japan in relapsing multiple sclerosis (RMS)*</td>
</tr>
<tr>
<td><strong>TECVAYLI</strong> (teclistamab)</td>
<td>Discovered, developed &amp; commercialized by Janssen</td>
<td>Approved in U.S. &amp; EU for patients with relapsed and refractory MM*</td>
</tr>
<tr>
<td><strong>TEPEZZA</strong> (teprotumumab-trbw)</td>
<td>Developed and commercialized by Amgen</td>
<td>Approved in U.S. in thyroid eye disease (TED)*</td>
</tr>
<tr>
<td><strong>TALVEY</strong> (talquetamab-tgys)</td>
<td>Discovered, developed &amp; commercialized by Janssen</td>
<td>Approved in U.S. &amp; EU for patients with relapsed and refractory MM*</td>
</tr>
</tbody>
</table>

*See local prescribing information for full indication and safety information.
## 2024 Guidance

Recurring Revenue Growth and Focused Investments

<table>
<thead>
<tr>
<th>Key Figures (DKKM)</th>
<th>2024 Guidance</th>
<th>2024 Guidance Mid-Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>18,700 – 20,500</td>
<td>19,600</td>
</tr>
<tr>
<td>Royalties</td>
<td>15,600 – 16,700</td>
<td>16,150</td>
</tr>
<tr>
<td>Net Product Sales/Collaboration Revenue**</td>
<td>1,700 – 2,200</td>
<td>1,950</td>
</tr>
<tr>
<td>Milestones/Reimbursement Revenue</td>
<td>1,400 – 1,600</td>
<td>1,500</td>
</tr>
<tr>
<td>Gross Profit***</td>
<td>18,000 – 19,500</td>
<td>18,750</td>
</tr>
<tr>
<td>Operating Expenses***</td>
<td>(12,400) – (13,400)</td>
<td>(12,900)</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>4,600 – 7,100</td>
<td>5,850</td>
</tr>
</tbody>
</table>

*Mid-point of guidance range  
**Net Product Sales and Collaboration Revenue consists of EPKINLY Net Product Sales in the U.S. and Japan and Tivdak (Genmab’s share of net profits) in the U.S.  
***Operating Expenses Range excludes Cost of Product Sales Range, which is included in Gross Profit Range  

All amounts in DKK millions unless otherwise noted  
2024 guidance assumes a USD/DKK exchange rate of 6.8

Genmab Net Product Sales/Collaboration Revenue increasingly contributing to revenue growth

Growth in operating expenses to support expanding mid / late-stage development programs – EPKINLY, Tivdak, Acasunlimab (GEN1046) and GEN1042

Underlying profitability back to significant growth
2024 Priorities:

Bring Our Own Medicines to Patients & Expand Our Markets

EPKINLY¹
- Initiate three Phase 3 trials
- Expand epcoritamab label to include R/R FL

Tivdak²
- Initiate Phase 3 study in H&N

Execute successful launches & growth in key markets

Further Advancing Our Differentiated Product Pipeline Towards The Market

Build World-class Differentiated Pipeline

Acasunlimab (GEN1046)³
- Initiate Phase 3 study (2L NSCLC)

GEN1042 (DuoBody-CD40x4-1BB)³
- Phase 2 data and determine next steps

Expand and advance proprietary product portfolio

Invest in Our People, Culture & Society

Further scale organization aligned with differentiated antibody product portfolio growth and future launches

Become a Leading Integrated Biotech Innovation Powerhouse

Use solid financial base to grow and broaden antibody product and technology portfolio

¹ Co-development w/ AbbVie; ² Co-development w/ Pfizer; ³ Co-development w/ BioNTech
Driving Towards Our 2030 Vision

- Clear Vision
- Focused Strategy
- Effective Execution

Genmab Today
- 2 approved medicines
- Significant & growing recurring revenues
- Strong rationale to invest
- Focused & disciplined

Our Future
- Fully-integrated biotech innovation powerhouse

For Investor audience only. Not for public information or use. Not for promotional use.
A Leading International Biotech With Large Free Float

- Ordinary shares: Nasdaq Copenhagen, DK
- ADSs: Nasdaq Global Select USA
- Shares world-wide incl: US, DK, NL, UK
- Market Cap:
  - ~ DKK 144bn
  - ~ USD 21bn
- Shares outstanding: ~66M
Our Approach to Corporate Social Responsibility (CSR)

Genmab is committed to being a socially responsible and sustainable biotechnology company. Our commitment to CSR is anchored in our company’s purpose, values and vision. Being socially responsible is fundamental to the way we do business.

Our Approach

- Guided by our vision, purpose and core values
- Aligned with ESG priorities and disclosures
- Focused on four CSR pillars
- Supported by the Board of Directors and Executive Management
- Underpinned by our commitment to the UN SDGs

Our Pillars

- Science-Driven Health Innovations for Patients
- Employee Well-Being and Vitality
- Ethics and Transparency
- Environmental and Community Sustainability

Our Commitment to the UN Sustainable Development Goals

© Genmab 2024

For Investor audience only. Not for public information or use. Not for promotional use.
Genmab’s ESG Performance: Well-Rated Company

For Investor audience only. Not for public information or use. Not for promotional use.
## Innovation Powerhouse: Cutting Edge Proprietary Technologies

<table>
<thead>
<tr>
<th>Technology</th>
<th>Principle</th>
<th>Applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>DuoBody</td>
<td>Bispecific antibodies</td>
<td>Dual targeting</td>
</tr>
<tr>
<td>HexaBody</td>
<td>Target-mediated enhanced hexamerization</td>
<td>Enhanced potency</td>
</tr>
<tr>
<td>DuoHexaBody</td>
<td>Bispecific antibodies with target-mediated enhanced hexamerization</td>
<td>Dual targeting + enhanced potency</td>
</tr>
<tr>
<td>HexElect</td>
<td>Two co-dependent antibodies with target-mediated enhanced hexamerization</td>
<td>Dual targeting + enhanced potency &amp; selectivity</td>
</tr>
</tbody>
</table>
### Innovative Pipeline: Genmab’s Proprietary¹ Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Developed By</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epcoritamab</td>
<td>Co-development Genmab / AbbVie</td>
<td>Relapsed/refractory DLBCL</td>
<td>Preclinical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relapsed/refractory FL</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>First line DLBCL</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>First line FL</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B-cell NHL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Relapsed/refractory CLL &amp; Richter’s Syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aggressive mature B-cell neoplasms in pediatric patients</td>
<td></td>
</tr>
<tr>
<td>Tisotumab vedotin</td>
<td>Co-development Genmab / Pfizer</td>
<td>Cervical cancer</td>
<td>Preclinical</td>
</tr>
<tr>
<td>Acasunlimab (GEN1046/BNT311, DuoBody-PD-L1x4-1BB)</td>
<td>Co-development Genmab / BioNTech</td>
<td>Solid tumors</td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD40x4-1BB       (GEN1042/BNT312)</td>
<td>Co-development Genmab / BioNTech</td>
<td>NSCLC</td>
<td></td>
</tr>
<tr>
<td>HexaBody-CD38            (GEN3014)</td>
<td>Genmab²</td>
<td>Solid tumors</td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD3xCD30         (GEN3017)</td>
<td>Genmab</td>
<td>Hematologic malignancies</td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD3xCD30         (GEN3017)</td>
<td>Genmab</td>
<td>Solid tumors</td>
<td></td>
</tr>
<tr>
<td>HexaBody-CD27            (GEN1053/BNT313)</td>
<td>Co-development Genmab / BioNTech</td>
<td>Relapsed/refractory Hodgkin lymphoma &amp; NHL</td>
<td></td>
</tr>
<tr>
<td>DuoBody-EpCAMx4-1BB      (GEN1059/BNT314)</td>
<td>Co-development Genmab / BioNTech</td>
<td>Solid tumors</td>
<td></td>
</tr>
<tr>
<td>GEN1056 (BNT322)</td>
<td>Co-development Genmab / BioNTech</td>
<td>Solid tumors</td>
<td></td>
</tr>
</tbody>
</table>

¹Certain product candidates in development with partners, as noted; ²Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
## Programs Incorporating Genmab’s Innovation and Technology, ≥Phase 2 Development

<table>
<thead>
<tr>
<th>Product</th>
<th>Technology</th>
<th>Discovered and/or Developed By</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daratumumab</td>
<td>UltiMAb</td>
<td>Janssen</td>
<td>MM</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AL Amyloidosis</td>
<td></td>
</tr>
<tr>
<td>Teprotumab</td>
<td>UltiMAb</td>
<td>Amgen</td>
<td>TED</td>
<td></td>
</tr>
<tr>
<td>Amivantamab</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>NSCLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Advanced or metastatic gastric or esophageal cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatocellular carcinoma</td>
<td></td>
</tr>
<tr>
<td>Teclistamab</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>MM</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Talquetamab</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>MM</td>
<td></td>
</tr>
<tr>
<td>Inclacumab</td>
<td>UltiMAb</td>
<td>Pfizer</td>
<td>Vaso-occlusive crises in sickle cell disease</td>
<td></td>
</tr>
<tr>
<td>Mim8</td>
<td>DuoBody</td>
<td>Novo Nordisk</td>
<td>Hemophilia A</td>
<td></td>
</tr>
<tr>
<td>Ordesekimab</td>
<td>UltiMAb</td>
<td>Sanofi</td>
<td>Celiac disease</td>
<td></td>
</tr>
<tr>
<td>(PRV-015, AMG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>714)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lu AF82422</td>
<td>UltiMAb</td>
<td>Lundbeck</td>
<td>Multiple system atrophy</td>
<td></td>
</tr>
</tbody>
</table>
Our Goal in Cervical Cancer: Establish Tivdak® as a Clear Choice in 2L+ Settings

mCC Treatment Landscape

1L

~50% PD-L1+

Pembro + Chemotherapy +/- Bevacizumab* or Chemotherapy +/- Bevacizumab

~50% PD-L1-

Chemotherapy +/- Bevacizumab*

2L

~50% PD-L1+

Pembro**, Other IO**, or Chemo

~50% PD-L1-

All Patient Types

3L+

Pembrolizumab or Chemotherapy

Source: Kantar Treatment Architecture: Cervical Cancer; NCCN Treatment Guidelines;

*Pembrolizumab is approved in combination with chemo +/- bev in 1L for PD-L1 positive patients only in the US at this time, global filings to follow. Other IOs are also being evaluated in 1L treatment

**Pembrolizumab is approved for 2L r/mCC in the US; not approved in JPN or EU. Nivo is on NCCN guidelines for PD-L1 positive patients

© Genmab 2024
Rooted in Science, Inspired by Patients